Summary
Mitochondria produce most of the energy the body acquires through food, and are thus pivotal players in cellular metabolism. Central to mitochondrial biology is the DNA in the organelle (mtDNA): its maintenance, correct RNA processing, and efficient translation are all essential and must be coordinated to ensure proper mitochondrial function and cellular physiology. Defective maintenance or expression of mtDNA alters energy and nutrient metabolism, which are increasingly recognized to impact medical disciplines, ranging from hundreds of genetic disorders to neurodegeneration, immunology, transmissible disease, cancer and ageing. A deep understanding of the mitochondrial gene expression system and new methods are urgently needed to develop treatments for the full panoply of mitochondrial disorders that feature mtDNA perturbation.
MITGEST will unite world-class academic excellence in mtDNA maintenance and expression with private sector expertise in nucleic acid chemistry and the development of mitochondrial therapeutics to address this urgent need. As the first research training programme in this field to take a fully integrated approach, our 10 doctoral candidates (DC) will elucidate how mtDNA is maintained and expressed and support the development of new methods to analyse RNA and DNA metabolism in mitochondria. These advances will complement and facilitate/enhance innovative treatment strategies and experimental medicine studies designed to mitigate mitochondrial dysfunction in a range of human diseases.
Our network of 7 beneficiaries and 12 associated partners from 8 European countries and Israel builds on proven collaborations and establishes new partnerships to deliver intersectoral and multidisciplinary scientific and transferable skills training to our 11 PhD students to generate the next generation of highly-skilled scientists able to exploit the latest advances in mitochondrial biology and medicine.
MITGEST will unite world-class academic excellence in mtDNA maintenance and expression with private sector expertise in nucleic acid chemistry and the development of mitochondrial therapeutics to address this urgent need. As the first research training programme in this field to take a fully integrated approach, our 10 doctoral candidates (DC) will elucidate how mtDNA is maintained and expressed and support the development of new methods to analyse RNA and DNA metabolism in mitochondria. These advances will complement and facilitate/enhance innovative treatment strategies and experimental medicine studies designed to mitigate mitochondrial dysfunction in a range of human diseases.
Our network of 7 beneficiaries and 12 associated partners from 8 European countries and Israel builds on proven collaborations and establishes new partnerships to deliver intersectoral and multidisciplinary scientific and transferable skills training to our 11 PhD students to generate the next generation of highly-skilled scientists able to exploit the latest advances in mitochondrial biology and medicine.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/101072515 |
Start date: | 01-10-2022 |
End date: | 31-01-2027 |
Total budget - Public funding: | - 2 623 752,00 Euro |
Cordis data
Original description
Mitochondria produce most of the energy the body acquires through food, and are thus pivotal players in cellular metabolism. Central to mitochondrial biology is the DNA in the organelle (mtDNA): its maintenance, correct RNA processing, and efficient translation are all essential and must be coordinated to ensure proper mitochondrial function and cellular physiology. Defective maintenance or expression of mtDNA alters energy and nutrient metabolism, which are increasingly recognized to impact medical disciplines, ranging from hundreds of genetic disorders to neurodegeneration, immunology, transmissible disease, cancer and ageing. A deep understanding of the mitochondrial gene expression system and new methods are urgently needed to develop treatments for the full panoply of mitochondrial disorders that feature mtDNA perturbation.MITGEST will unite world-class academic excellence in mtDNA maintenance and expression with private sector expertise in nucleic acid chemistry and the development of mitochondrial therapeutics to address this urgent need. As the first research training programme in this field to take a fully integrated approach, our 10 doctoral candidates (DC) will elucidate how mtDNA is maintained and expressed and support the development of new methods to analyse RNA and DNA metabolism in mitochondria. These advances will complement and facilitate/enhance innovative treatment strategies and experimental medicine studies designed to mitigate mitochondrial dysfunction in a range of human diseases.
Our network of 7 beneficiaries and 12 associated partners from 8 European countries and Israel builds on proven collaborations and establishes new partnerships to deliver intersectoral and multidisciplinary scientific and transferable skills training to our 11 PhD students to generate the next generation of highly-skilled scientists able to exploit the latest advances in mitochondrial biology and medicine.
Status
SIGNEDCall topic
HORIZON-MSCA-2021-DN-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)